CL2020001908A1 - Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). - Google Patents
Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).Info
- Publication number
- CL2020001908A1 CL2020001908A1 CL2020001908A CL2020001908A CL2020001908A1 CL 2020001908 A1 CL2020001908 A1 CL 2020001908A1 CL 2020001908 A CL2020001908 A CL 2020001908A CL 2020001908 A CL2020001908 A CL 2020001908A CL 2020001908 A1 CL2020001908 A1 CL 2020001908A1
- Authority
- CL
- Chile
- Prior art keywords
- ghrelin
- acyltransferase
- goat
- inhibitors
- heterocyclyl substituted
- Prior art date
Links
- 241000283707 Capra Species 0.000 title abstract 2
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 title abstract 2
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical class C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula general I, en donde las variables X, R1, n, p y q se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-aciltransferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154828 | 2018-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001908A1 true CL2020001908A1 (es) | 2020-10-30 |
Family
ID=61157053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001908A CL2020001908A1 (es) | 2018-02-02 | 2020-07-21 | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11319310B2 (es) |
| EP (1) | EP3746450B1 (es) |
| JP (1) | JP7150032B2 (es) |
| KR (1) | KR20200118124A (es) |
| CN (1) | CN111655699B (es) |
| AU (1) | AU2019215709A1 (es) |
| BR (1) | BR112020014320A2 (es) |
| CA (1) | CA3087827A1 (es) |
| CL (1) | CL2020001908A1 (es) |
| CO (1) | CO2020009179A2 (es) |
| CR (1) | CR20200331A (es) |
| EA (1) | EA202091804A1 (es) |
| EC (1) | ECSP20050791A (es) |
| IL (1) | IL276137A (es) |
| JO (1) | JOP20200191A1 (es) |
| MA (1) | MA53074A (es) |
| MX (1) | MX2020008116A (es) |
| PE (1) | PE20210175A1 (es) |
| PH (1) | PH12020551169A1 (es) |
| SG (1) | SG11202006300XA (es) |
| WO (1) | WO2019149659A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017307033B2 (en) * | 2016-08-05 | 2020-11-26 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| MA53075A (fr) | 2018-02-02 | 2021-05-12 | Boehringer Ingelheim Int | Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) |
| US11583532B2 (en) | 2018-02-02 | 2023-02-21 | Boehringer Ingelheim International Gmbh | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors |
| JP7225253B2 (ja) * | 2018-02-02 | 2023-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体 |
| EP4153600A1 (en) | 2020-05-22 | 2023-03-29 | Boehringer Ingelheim International GmbH | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| EP4153599B1 (en) | 2020-05-22 | 2024-03-13 | Boehringer Ingelheim International GmbH | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082383A1 (en) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Use of triazolopyrimidines for combating nematode diseases of plants |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070251A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| BRPI0823376A2 (pt) | 2008-12-15 | 2015-06-16 | Zealand Pharma As | Análagos de glucagon |
| JP5635532B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| CA2802897A1 (en) | 2010-06-24 | 2011-12-29 | Zealand Pharma A/S | Glucagon analogues |
| MX2014007120A (es) | 2011-12-23 | 2015-03-05 | Boehringer Ingelheim Int | Analogos de glucagon. |
| CN104254525B (zh) | 2012-02-24 | 2016-05-25 | 武田药品工业株式会社 | 芳环化合物 |
| WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (en) | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| US10131642B1 (en) | 2015-01-30 | 2018-11-20 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AU2017307033B2 (en) * | 2016-08-05 | 2020-11-26 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors |
-
2019
- 2019-01-28 KR KR1020207025418A patent/KR20200118124A/ko unknown
- 2019-01-28 AU AU2019215709A patent/AU2019215709A1/en not_active Abandoned
- 2019-01-28 SG SG11202006300XA patent/SG11202006300XA/en unknown
- 2019-01-28 BR BR112020014320-0A patent/BR112020014320A2/pt not_active Application Discontinuation
- 2019-01-28 CN CN201980010384.6A patent/CN111655699B/zh active Active
- 2019-01-28 US US16/966,489 patent/US11319310B2/en active Active
- 2019-01-28 MX MX2020008116A patent/MX2020008116A/es unknown
- 2019-01-28 PE PE2020001163A patent/PE20210175A1/es unknown
- 2019-01-28 JO JOP/2020/0191A patent/JOP20200191A1/ar unknown
- 2019-01-28 WO PCT/EP2019/051993 patent/WO2019149659A1/en unknown
- 2019-01-28 JP JP2020541870A patent/JP7150032B2/ja active Active
- 2019-01-28 CA CA3087827A patent/CA3087827A1/en not_active Abandoned
- 2019-01-28 MA MA053074A patent/MA53074A/fr unknown
- 2019-01-28 EA EA202091804A patent/EA202091804A1/ru unknown
- 2019-01-28 CR CR20200331A patent/CR20200331A/es unknown
- 2019-01-28 EP EP19702085.2A patent/EP3746450B1/en active Active
-
2020
- 2020-07-19 IL IL276137A patent/IL276137A/en unknown
- 2020-07-21 CL CL2020001908A patent/CL2020001908A1/es unknown
- 2020-07-24 CO CONC2020/0009179A patent/CO2020009179A2/es unknown
- 2020-07-31 PH PH12020551169A patent/PH12020551169A1/en unknown
- 2020-08-24 EC ECSENADI202050791A patent/ECSP20050791A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200118124A (ko) | 2020-10-14 |
| US20210040077A1 (en) | 2021-02-11 |
| CN111655699B (zh) | 2023-07-14 |
| CR20200331A (es) | 2020-09-03 |
| EA202091804A1 (ru) | 2020-12-24 |
| BR112020014320A2 (pt) | 2020-12-08 |
| EP3746450A1 (en) | 2020-12-09 |
| CN111655699A (zh) | 2020-09-11 |
| CA3087827A1 (en) | 2019-08-08 |
| PE20210175A1 (es) | 2021-01-29 |
| EP3746450B1 (en) | 2022-03-16 |
| MX2020008116A (es) | 2020-09-25 |
| IL276137A (en) | 2020-09-30 |
| WO2019149659A1 (en) | 2019-08-08 |
| MA53074A (fr) | 2021-05-12 |
| PH12020551169A1 (en) | 2021-05-31 |
| SG11202006300XA (en) | 2020-07-29 |
| JP7150032B2 (ja) | 2022-10-07 |
| ECSP20050791A (es) | 2020-09-30 |
| CO2020009179A2 (es) | 2020-07-31 |
| JP2021512112A (ja) | 2021-05-13 |
| JOP20200191A1 (ar) | 2020-07-29 |
| AU2019215709A1 (en) | 2020-07-16 |
| US11319310B2 (en) | 2022-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009179A2 (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP20050797A (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP20050785A (es) | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) | |
| CO2019000601A2 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| CO2017011216A2 (es) | Compuestos heterocíclicos como inhibidores de lsd1. | |
| CO2018008173A2 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| CO2019014455A2 (es) | Amidas heterocíclicas de 5 miembros y bicíclicas como inhibidores de rock | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| BR112020008817B8 (pt) | Compostos moduladores da via de estresse integrada | |
| CU24389B1 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| BR112017012272A2 (pt) | derivados de 2-anilinopirimidina como moduladores de egfr | |
| NI201400043A (es) | 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| ECSP15004780A (es) | Antagonistas del receptor de 5ht3 | |
| BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
| UY35312A (es) | Ácidos indaniloxidihidrobenzofuranilacéticos como agonistas del receptor acoplado a la proteína g40 | |
| MX2020003862A (es) | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). | |
| UY36326A (es) | N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| CR20160428A (es) | Pizazinas moduladoras de gpr6 | |
| BR112017013194A2 (pt) | síntese total de trioxacarcina dc-45-a2 e preparação de análogos de trioxacarcina |